Onderzoeksgraad Bemarituzumab

Bemarituzumab (bema), afirst-in-classhumanizedIgG1monoclonalantibody, selectivelybindsto2bIsoformofthefibroblastgrowthfactorreceptor (FGFR2b) .Bemarituzumab (FPA144) isafirst-in-classhumanizedimmunoglobulinG1monoclonalantibodyspecifictothesplice-variantFGFR2bthatinhibitsbindingoftheligandsFGF7, FGF10, andFGF22.Specifically, bemarituzumabdoesnotinhibitbindingofFGF23, theligandresponsibleforphosphateandvitaminDmetabolism, therebypotentiallyavoidingtheriskofhyperphosphatemiaassociatedwithpan-FGFRtyrosinekinaseinhibitors.BemarituzumabisalsoglycoengineeredforincreasedaffinityforthehumanFcgammaRIIIAreceptorexpressedonnaturalkillercells, enablingenhancedantibody-dependentcell_x0002_mediatedcytotoxicity.

FPA144, FPA-144, FPA114-A, CAS:1952272-74-0

Mammalian Cells

K-sam, KSAM, CD332, Keratinocytegrowthfactorreceptor, Fibroblastgrowthfactorreceptor2, FGFR-2, FGFR2, KGFR, BEK

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -365°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

Human

IgG1-kappa